BACKGROUND: We investigated the impact of staphylococcal carriage among patients on continuous peritoneal dialysis (CPD) in a university hospital. METHODS: Patients were screened for Staphylococcus aureus carriage and categorized as persistent, intermittent, or non-S. aureus nasal carriers. Patients were subsequently recultured every 12 weeks for S. aureus and coagulase negative staphylococcal (CoNS) carriage, and followed-up for CPD-related infections and antibiotic resistance. RESULTS: Fifty-two patients were included: 20 peristent, 10 intermittent, and 22 non-S. aureus carriers. Only persistent S. aureus carriage was significantly associated with an increased risk for all CPD-related infections [incidence rate ratio (IRR) 3.52 (95% CI: 2.56-4.85)], exit site infections [IRR 5.59 (95% CI: 3.50-8.92)], and peritonitis [IRR 2.19 (95% CI: 1.39-3.45)], as well as increased antibiotic use [IRR 3.43 (95% CI: 2.50-4.72)], including vancomycin [IRR 2.15 (95%: 2.13-2.16)]. No vancomycin-resistant S. aureus strains were detected. However, eight (2%) out of 407 CoNS strains isolated were vancomycin intermediately susceptible. In all five patients (four persistent and one intermittent carriers) concerned, this was significantly related to a higher antibiotic (including vancomycin) usage [IRR 2.65 (95% CI: 1.82-3.84)]. CONCLUSION: Persistent-but not intermittent-S. aureus nasal carriage is the major determinant of CPD-related infections, and is associated with a significantly higher consumption of antibiotics, including vancomycin. The highly diverse population of CoNS appears to be the prime reservoir of staphylococcal vancomycin resistance. Accurate determination of the S. aureus nasal carriage state of CPD patients is essential to better target intervention strategies to prevent CPD-related infections.
BACKGROUND: We investigated the impact of staphylococcal carriage among patients on continuous peritoneal dialysis (CPD) in a university hospital. METHODS:Patients were screened for Staphylococcus aureus carriage and categorized as persistent, intermittent, or non-S. aureus nasal carriers. Patients were subsequently recultured every 12 weeks for S. aureus and coagulase negative staphylococcal (CoNS) carriage, and followed-up for CPD-related infections and antibiotic resistance. RESULTS: Fifty-two patients were included: 20 peristent, 10 intermittent, and 22 non-S. aureus carriers. Only persistent S. aureus carriage was significantly associated with an increased risk for all CPD-related infections [incidence rate ratio (IRR) 3.52 (95% CI: 2.56-4.85)], exit site infections [IRR 5.59 (95% CI: 3.50-8.92)], and peritonitis [IRR 2.19 (95% CI: 1.39-3.45)], as well as increased antibiotic use [IRR 3.43 (95% CI: 2.50-4.72)], including vancomycin [IRR 2.15 (95%: 2.13-2.16)]. No vancomycin-resistant S. aureus strains were detected. However, eight (2%) out of 407 CoNS strains isolated were vancomycin intermediately susceptible. In all five patients (four persistent and one intermittent carriers) concerned, this was significantly related to a higher antibiotic (including vancomycin) usage [IRR 2.65 (95% CI: 1.82-3.84)]. CONCLUSION: Persistent-but not intermittent-S. aureus nasal carriage is the major determinant of CPD-related infections, and is associated with a significantly higher consumption of antibiotics, including vancomycin. The highly diverse population of CoNS appears to be the prime reservoir of staphylococcal vancomycin resistance. Accurate determination of the S. aureus nasal carriage state of CPD patients is essential to better target intervention strategies to prevent CPD-related infections.
Authors: Nitija Tiwari; Marisa López-Redondo; Laura Miguel-Romero; Katarina Kulhankova; Michael P Cahill; Phuong M Tran; Kyle J Kinney; Samuel H Kilgore; Hassan Al-Tameemi; Christine A Herfst; Stephen W Tuffs; John R Kirby; Jeffery M Boyd; John K McCormick; Wilmara Salgado-Pabón; Alberto Marina; Patrick M Schlievert; Ernesto J Fuentes Journal: Proc Natl Acad Sci U S A Date: 2020-04-30 Impact factor: 11.205
Authors: Jan Nouwen; Jeroen Schouten; Peter Schneebergen; Susan Snijders; Jolanda Maaskant; Marjan Koolen; Alex van Belkum; Henri A Verbrugh Journal: J Clin Microbiol Date: 2006-06 Impact factor: 5.948
Authors: Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis Journal: J Am Soc Nephrol Date: 2014-03-20 Impact factor: 10.121
Authors: C Garcia; A Acuña-Villaorduña; A Dulanto; S Vandendriessche; M Hallin; J Jacobs; O Denis Journal: Eur J Clin Microbiol Infect Dis Date: 2015-10-29 Impact factor: 3.267
Authors: Sharon J Nessim; Joanne M Bargman; Peter C Austin; Ken Story; Sarbjit V Jassal Journal: Clin J Am Soc Nephrol Date: 2008-11-05 Impact factor: 8.237